BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34253166)

  • 41. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence.
    Sun C; Fu B; Gao Y; Liao X; Sun R; Tian Z; Wei H
    PLoS Pathog; 2012; 8(3):e1002594. PubMed ID: 22438812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta.
    Lee HM; Kim KS; Kim J
    Cell Immunol; 2014 Jul; 290(1):52-61. PubMed ID: 24879062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TGF-β-mediated exosomal lnc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression.
    Wu DM; Deng SH; Liu T; Han R; Zhang T; Xu Y
    Cancer Med; 2018 Oct; 7(10):5118-5129. PubMed ID: 30256540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
    Huang Y; Wang Y; Li Y; Guo K; He Y
    J Cancer Res Clin Oncol; 2011 May; 137(5):829-37. PubMed ID: 20809412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "Acquired" NKG2D Ligand Stimulates NK Cell-mediated Tumor Immunosurveillance.
    Wang D; Gu X; Liu X; Liu X; Wang B; Lao F; Fang M
    J Immunother; 2019; 42(6):189-196. PubMed ID: 31145234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.
    Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T
    Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluoroquinolones Suppress TGF-β and PMA-Induced MMP-9 Production in Cancer Cells: Implications in Repurposing Quinolone Antibiotics for Cancer Treatment.
    Huang CY; Yang JL; Chen JJ; Tai SB; Yeh YH; Liu PF; Lin MW; Chung CL; Chen CL
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment.
    Lim KS; Mimura K; Kua LF; Shiraishi K; Kono K
    J Immunother; 2018; 41(6):261-273. PubMed ID: 29683892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Smoking attenuates transforming growth factor-β-mediated tumor suppression function through downregulation of Smad3 in lung cancer.
    Samanta D; Gonzalez AL; Nagathihalli N; Ye F; Carbone DP; Datta PK
    Cancer Prev Res (Phila); 2012 Mar; 5(3):453-63. PubMed ID: 22232600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
    Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
    Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural killer cell-mediated shedding of ULBP2.
    Wang R; Sun PD
    PLoS One; 2014; 9(3):e91133. PubMed ID: 24614922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells.
    López-Cobo S; Romera-Cárdenas G; García-Cuesta EM; Reyburn HT; Valés-Gómez M
    Immunology; 2015 Sep; 146(1):70-80. PubMed ID: 25980678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
    Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
    Huang YX; Chen XT; Guo KY; Li YH; Wu BY; Song CY; He YJ
    J Immunother; 2017 Jun; 40(5):164-174. PubMed ID: 28452850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Distribution of transforming growth factor-beta and its receptor in bronchiolo-alveolar cell hyperplasia and bronchiolo-alveolar carcinoma].
    Zeng Q; Jiang H; Yan Y; Qian Z
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(4):345-8. PubMed ID: 11189389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes.
    Ashiru O; Boutet P; Fernández-Messina L; Agüera-González S; Skepper JN; Valés-Gómez M; Reyburn HT
    Cancer Res; 2010 Jan; 70(2):481-9. PubMed ID: 20068167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
    Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
    J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pertussis toxin (PTX) B subunit and the nontoxic PTX mutant PT9K/129G inhibit Tat-induced TGF-beta production by NK cells and TGF-beta-mediated NK cell apoptosis.
    Zocchi MR; Contini P; Alfano M; Poggi A
    J Immunol; 2005 May; 174(10):6054-61. PubMed ID: 15879099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
    Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
    PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
    Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
    Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.